SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors react to the successful Artemis II mission and growing anticipation surrounding potential upcoming lunar contracts. The community is actively discussing the stock's significant momentum, potential for a short squeeze, and its emergence as a key player in the expanding private space infrastructure sector.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is facing heavy selling pressure amid a broader market rotation out of high-multiple software stocks, with investors weighing concerns over long-term AI disruption against its strong product retention. While many traders see the current weakness as an overreaction and a potential accumulation opportunity, sentiment remains divided as the community debates whether the stock is finding a bottom or heading toward lower valuations.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is experiencing significant volatility and trading interest as investors weigh the company's substantial cash position against a pivotal upcoming clinical data readout. Community sentiment is deeply divided, with some traders optimistic about potential institutional accumulation and buyout speculation, while others express concerns over the stock's recent price decline and the long timeline to future trial milestones.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is experiencing significant upward momentum driven by a $2 billion strategic investment from Nvidia aimed at bolstering AI infrastructure and cloud connectivity. The community is actively discussing the stock's transition from a standard semiconductor play to a critical AI infrastructure bet, with many investors anticipating further price appreciation as optics and custom AI chips become essential components for hyperscalers.

GraniteShares ETF Trust - GraniteShares 2x Long NBIS Daily ETF

GraniteShares 2x Long NBIS Daily ETF

The GraniteShares 2x Long NBIS Daily ETF (NBIL) is trending as traders utilize the vehicle to capture leveraged exposure to the price movements of Nebius Group (NBIS). Community members are actively sharing their swing-trading strategies and entry points, driven by both technical setups and high expectations for potential growth in the underlying stock.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending as institutional investors aggressively de-risk from the enterprise SaaS sector, with sentiment pressured by fears that generative AI tools could disrupt traditional workflow management models. Despite persistent selling and fresh 52-week lows, the community remains deeply divided between those viewing the stock as a structurally broken "value trap" and contrarian investors who argue the platform's deep integration and enterprise switching costs provide a durable moat against AI-native competition.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is experiencing intense volatility as investors debate whether AI advancements from companies like Anthropic will disrupt traditional SaaS business models or if the recent sell-off represents a generational buying opportunity. Community sentiment is deeply divided, with many traders pointing to high short interest and technical support levels as signs of a potential bottom, while others express concern over long-term structural risks to software valuations.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is facing significant volatility as investors weigh strong quarterly growth and record contract signings against concerns regarding AI-driven SaaS disruption and cautious guidance. The stock is currently caught in a broader software sector selloff, with community sentiment deeply divided between long-term bulls highlighting data infrastructure demand and bears pointing to technical breakdowns, insider selling, and the threat of next-generation AI models.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation (DAG) is attracting significant community attention due to its focus on enterprise-grade data validation and its existing contracts with U.S. defense agencies. Investors are highlighting its unique DAG-based architecture as a scalable alternative to traditional blockchains, positioning it as a key infrastructure play for the growing AI and secure data integrity sectors.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

ALOY is trending as investors focus on its role in the U.S. defense supply chain following a recent capital raise and government contracts. Community discussion centers on its long-term potential in rare earth processing versus skepticism regarding its pre-revenue status and recent price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update PR Newswire SHELTON, Conn., March 27, 2026 Raised over $20 million in gross...

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US PR Newswire SHELTON, Conn...

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical...

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement PR Newswire SHELTON, Conn...

<ul class="summary-bullets"><li>After the adjustment, Intensity Therapeutics stock will begin trading on February 19, retaining the ticker symbol INTS.</li><li>The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million.</li><li>In January, the company said it raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027.&nbsp;</li></ul>Intensity Therapeutics, Inc. (INTS) on Friday announced a 1-for-25 reverse stock split approved by its board and shareholders, aiming to boost the per-share price of its common stock to meet Nasdaq’s minimum listing requirements.The reverse split, scheduled to take effect at 4:01 p.m. ET on February 18, will consolidate every 25 existing shares into a single new share.<h2 class="st-heading-2">Changes After The Reverse Split</h2>After the adjustment, Intensity Therapeutics stock will begin trading on February 19, under a new CUSIP number 45828J 202 while retaining the ticker symbol INTS.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/INTS">Intensity Therapeutics stock&nbsp;</a>traded 25% lower on Friday morning.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;Intensity is a late-stage biotech company developing its own cancer treatments. It uses a special drug-linking technology to create therapies that aim to destroy tumors and help the immune system better detect cancer.<h2 class="st-heading-2">Impact on Shareholders</h2>The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million. No fractional shares will be issued; instead, shareholders entitled to a fraction will receive cash payments based on the adjusted closing price on February 18.Alongside the split, the company will make proportional changes to stock options, warrants, convertible securities, and shares issued under its stock incentive programs. The total number of authorized shares will remain unchanged.In January, the company outlined its 2025 achievements and mapped out priorities for 2026 as it advances INT230-6, its lead cancer therapy designed to destroy tumors and stimulate immune response. Intensity raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027.&nbsp;INTS stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-slips-premarket-ev-headwinds-mount-wall-street-sees-upside-physical-ai-future/cZR5NHfR4sm">Tesla Stock Slips Premarket As EV Headwinds Mount — But One Wall Street Firm Sees Over 30% Upside On A ‘Physical AI’ Future</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did INTS Stock Plummet 25% Today? 

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.

Equity

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.


Intensity Therapeutics Announces Reverse Stock Split

Intensity Therapeutics Announces Reverse Stock Split Intensity Therapeutics Announces Reverse Stock Split PR Newswire SHELTON, Conn., Feb. 13, 2026 Intensity's common stock is expected to begin...

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities PR Newswire SHELTON...

All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy

Intensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium...

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's...

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

INTS
INTENSITY THERAPEUTICS, INC.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INTS News

INTSINTENSITY THERAPEUTICS, INC.